Heliox as a driving gas to atomize inhaled drugs on acute exacerbation of chronic obstructive pulmonary disease: a prospective clinical study  被引量:4

Heliox as a driving gas to atomize inhaled drugs on acute exacerbation of chronic obstructive pulmonary disease: a prospective clinical study

在线阅读下载全文

作  者:Xiao Yongjiu Su Longxiang Han Bingchao Zhang Xin Xie Lixin 

机构地区:[1]Department of Respiratory Medicine, Chinese People's Liberation Army General Hospital, Beijing 100853, China [2]Department of Respiratory Medicine, Lanzhou General Hospital ofLanzhou Military Area Command of Chinese People's LiberationArmy, Lanzhou, Gansu 730050, China [3]Medical College of Nankai University, Tianjin 300071, China [4]Department of Respiratory Medicine, Bethune International PeaceHospital, Shijiazhuang, Hebei 050082, China

出  处:《Chinese Medical Journal》2014年第1期29-35,共7页中华医学杂志(英文版)

摘  要:Background Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is a common condition,which affects not only the quality of life of patients but also their prognosis.The purpose of this study was to explore the effects of an inhaled salbutamol sulfate solution and an inhalation suspension of the glucocorticoid budesonide that were atomized with heliox to treat patients with AECOPD.Methods Twenty-three patients with AECOPD were divided into a treatment group (He/O2=70%/30%) and a control group (N2/O2=70%/30%).The salbutamol sulfate and budesonide were administered by inhalation twice a day for 7 days.Vital signs,arterial blood gas levels,pulmonary function and the levels of serum myostatin (sMSTN) were measured and lung vibration imaging was performed.Results We found that the PaO2 and PaCO2 values were not significantly different between the two groups at the various time points (P >0.05).There were also no significant differences in any of the parameters of pulmonary function between the two groups.However,after baseline correction,the increase rate of the forced expiratory volume in one second (FEV1),the forced vital capacity (FVC),and the maximum minute ventilation (MW) appeared to be significantly increased at some time points compared with the baseline (before treatment) in both groups (P <0.05).Although the values of quantitative lung distribution (QLD) for different regions and the levels of sMSTN were slightly different between the two groups,the repeated measures analysis of variance (ANOVA) revealed that there were no significant differences between the two groups or within any group (P >0.05).Conclusion Although the use of heliox as a driving gas can improve symptoms and benefit patients with AECOPD,the heliox treatment group did not have significant differences in arterial blood gases,lung function,lung vibration response imaging or the levels of sMSTN compared with the control group.(Chinese Clinical Trial Register CeBackground Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is a common condition,which affects not only the quality of life of patients but also their prognosis.The purpose of this study was to explore the effects of an inhaled salbutamol sulfate solution and an inhalation suspension of the glucocorticoid budesonide that were atomized with heliox to treat patients with AECOPD.Methods Twenty-three patients with AECOPD were divided into a treatment group (He/O2=70%/30%) and a control group (N2/O2=70%/30%).The salbutamol sulfate and budesonide were administered by inhalation twice a day for 7 days.Vital signs,arterial blood gas levels,pulmonary function and the levels of serum myostatin (sMSTN) were measured and lung vibration imaging was performed.Results We found that the PaO2 and PaCO2 values were not significantly different between the two groups at the various time points (P >0.05).There were also no significant differences in any of the parameters of pulmonary function between the two groups.However,after baseline correction,the increase rate of the forced expiratory volume in one second (FEV1),the forced vital capacity (FVC),and the maximum minute ventilation (MW) appeared to be significantly increased at some time points compared with the baseline (before treatment) in both groups (P <0.05).Although the values of quantitative lung distribution (QLD) for different regions and the levels of sMSTN were slightly different between the two groups,the repeated measures analysis of variance (ANOVA) revealed that there were no significant differences between the two groups or within any group (P >0.05).Conclusion Although the use of heliox as a driving gas can improve symptoms and benefit patients with AECOPD,the heliox treatment group did not have significant differences in arterial blood gases,lung function,lung vibration response imaging or the levels of sMSTN compared with the control group.(Chinese Clinical Trial Register Ce

关 键 词:chronic obstructive pulmonary disease HELIOX arterial blood gas pulmonary function vibration response imaging MYOSTATIN 

分 类 号:TQ460.69[化学工程—制药化工] Q51[生物学—生物化学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象